CJC-1295 Compounding Pharmacy: How to Read a Certificate of Analysis

What a Certificate of Analysis Actually Is

A certificate of analysis is a batch-specific quality document produced by an independent or in-house analytical laboratory confirming that a compounded preparation meets its stated specifications. For CJC-1295, the CoA should accompany every dispensed vial, and it should be traceable to a specific lot number stamped on that vial.

The document is not marketing material. A genuine CoA references the analytical method used (for example, reverse-phase HPLC with UV detection at 220 nm), the instrument calibration date, the lot number tested, the date of testing, and the name and address of the testing laboratory. If any of those fields are blank, the CoA cannot be verified.

FDA 21 CFR Part 211 requires that pharmaceutical manufacturers maintain records of each test performed on a batch, and while compounding pharmacies operate under a different section of law, the same evidentiary principle applies. The FDA has issued warning letters specifically citing inadequate quality testing at compounding facilities, including failures to perform identity and potency testing before dispensing sterile preparations. [1]

Why CJC-1295 Specifically Demands a CoA

CJC-1295 is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH). It is supplied as a lyophilized powder and reconstituted for subcutaneous injection. The injectable route means any contamination, pyrogen, or incorrect concentration reaches systemic circulation immediately. There is no gastrointestinal barrier to slow or filter an error.

A 2020 FDA analysis of compounded drug samples found that approximately 36% of sampled units from online and retail compounding sources failed at least one quality test, including potency and sterility failures. [2] That figure alone justifies treating the CoA as non-negotiable.

The Molecular Identity Problem

CJC-1295 is sold in two distinct forms: with drug affinity complex (DAC) and without DAC. The DAC modification attaches albumin-binding groups that extend the half-life from roughly 30 minutes (without DAC) to approximately 6 to 8 days (with DAC). [3] A CoA that does not confirm molecular weight by mass spectrometry cannot distinguish between the two forms. Requesting LC-MS or high-resolution mass spectrometry (HRMS) data is the only way to confirm you have received the correct molecule at the correct mass.

The Regulatory Framework Governing CJC-1295 Compounding

CJC-1295 compounding sits at the intersection of several overlapping regulatory bodies. Understanding the hierarchy matters because it tells you which standards a pharmacy is actually obligated to meet, and which standards are aspirational.

Federal Law: Section 503A and 503B of the FD&C Act

Compounding pharmacies in the United States operate under two federal pathways. Section 503A pharmacies compound for individual patient prescriptions; they are regulated primarily by state boards of pharmacy and must comply with USP <797> for sterile preparations. Section 503B pharmacies (outsourcing facilities) register with the FDA, undergo routine FDA inspections, and may produce larger batches without patient-specific prescriptions. [4]

CJC-1295 is not on the FDA's 503B bulks list as a nominated bulk drug substance with a positive evaluation. Compounding it under 503B for non-patient-specific use occupies a legally gray area. The Endocrine Society's 2023 clinical practice guidelines on growth hormone disorders recommend against using compounded GH secretagogues as substitutes for FDA-approved growth hormone, citing insufficient evidence for efficacy and safety. [5]

USP <797>: The Sterility Standard That Governs Injectable Peptides

The 2023 revision of USP <797> (effective November 2023) tightened requirements significantly. Key changes include stricter beyond-use dating tied to container closure integrity testing (CCIT), mandatory environmental monitoring with action and alert levels for airborne and surface contamination, and clearer personnel training and competency requirements. [6]

Any pharmacy compounding CJC-1295 for injection must comply with USP <797>. The CoA you receive should reference the category of preparation (Category 1 or Category 2 under the revised framework) and confirm that the beyond-use date assigned is supported by either published stability data or facility-specific stability testing.

DSCSA Track-and-Trace Requirements

The Drug Supply Chain Security Act (DSCSA), fully enforced from November 2024, requires lot-level traceability across the pharmaceutical supply chain. While compounders are not "manufacturers" under DSCSA in the traditional sense, the raw active pharmaceutical ingredient (API) they source must come from an FDA-registered facility. A CoA for the raw CJC-1295 API should include the supplier's FDA registration number. Without that, the sourcing chain is unverifiable. [7]

Reading Each Section of a CJC-1295 CoA Line by Line

The following framework is used by the HealthRX medical review team when evaluating CoAs submitted by compounding pharmacy partners. Apply it in order.

Section 1: Header and Lot Traceability

| CoA Field | What to Check | |---|---| | Product name | Must specify "CJC-1295" and note presence or absence of DAC | | Lot number | Must match the vial label exactly | | Manufacture date | Must be present; initiates the BUD clock | | Testing lab name and address | Must be an independent third-party lab, not the compounding pharmacy itself | | Lab accreditation | ISO 17025 or equivalent analytical accreditation preferred |

A pharmacy that tests its own product without independent verification introduces an obvious conflict of interest. The FDA's 2012 New England Compounding Center (NECC) meningitis outbreak, which caused 64 deaths, was partly attributed to the absence of independent quality oversight. [8]

Section 2: Purity by HPLC

Reverse-phase HPLC is the gold standard for peptide purity testing. The CoA should state:

• The purity percentage by area under the curve (AUC), with 98% as the accepted minimum for injectable use.
• The column type and mobile phase used (for example, C18 column, acetonitrile/water gradient with 0.1% trifluoroacetic acid).
• The wavelength of UV detection (220 nm for peptide bonds is standard).
• A chromatogram image or a peak table showing all detected peaks.

A single purity number without the supporting chromatogram is insufficient. Related substances (impurities, degradation products, synthesis byproducts) should each be listed individually. Any single impurity above 0.5% warrants an explanation.

Section 3: Identity Confirmation by Mass Spectrometry

HPLC confirms purity but not identity. A compound could be 99% pure and still be the wrong peptide. Mass spectrometry closes that gap. For CJC-1295 with DAC, the expected average molecular weight is approximately 4,539 Da. For CJC-1295 without DAC (the modified GRF 1-29 form), it is approximately 3,367 Da. [3]

The CoA should show the observed m/z value and the charge states detected (for example, [M+3H]3+ and [M+4H]4+), with the calculated mass matching the theoretical within a tolerance of 0.1 Da or better for high-resolution instruments.

Section 4: Sterility Testing Under USP <71>

Sterility testing under USP <71> requires a 14-day incubation period in both thioglycolate medium (for anaerobes and aerobes) and soybean-casein digest medium (for aerobes and fungi). The CoA result for sterility must read "Conforms" or "Pass." Any result other than a clean pass is grounds to reject the batch entirely.

The test is destructive and performed on a statistical sample of units from the batch. It does not guarantee every vial is sterile, which is why the compounding environment itself (cleanroom classification, environmental monitoring) provides the primary sterility assurance, with the sterility test as a final check. [6]

Section 5: Bacterial Endotoxin Testing (BET) Under USP <85>

Endotoxins are lipopolysaccharide fragments from gram-negative bacterial cell walls. Even if a preparation is sterile (no live bacteria), residual endotoxins can cause fever, septic shock, and organ failure. The Limulus Amebocyte Lysate (LAL) test, described under USP <85>, is the standard method. [9]

The acceptable limit for parenteral drugs is 5 EU/mL, but the dose-based calculation matters more. The formula is: limit (EU/kg/dose) = K / M, where K is 5 EU/kg for non-intrathecal routes and M is the maximum dose in mL/kg. For typical CJC-1295 doses (0.1 to 0.3 mg, approximately 0.3 to 1.0 mL), the endotoxin result should be well below 2 EU/kg/dose. Any CoA showing a result above that threshold, or showing the result in EU/mL without a dose-based calculation, should be questioned.

Section 6: Potency and Concentration

The CoA should confirm the stated concentration (typically 2 mg/mL or 5 mg/mL for reconstituted CJC-1295) within a 90% to 110% range of label claim. Potency outside that range means you are receiving either less active drug than prescribed or more, both of which affect dosing accuracy.

Section 7: Beyond-Use Date and Storage Conditions

The beyond-use date (BUD) must be assigned based on either USP <797> default BUDs or facility-specific stability data. For Category 2 sterile preparations stored refrigerated (2 to 8 degrees C), USP <797> (2023) allows a BUD of up to 45 days. If the pharmacy claims a longer BUD, they must provide supporting stability data on the CoA or in an accompanying document. Storage conditions on the CoA must match the label on the vial.

How to Choose a Compounding Pharmacy for CJC-1295

PCAB Accreditation as a Starting Filter

The Pharmacy Compounding Accreditation Board (PCAB) is a voluntary accreditation program that audits compounding pharmacies against USP <795> and <797> standards. PCAB-accredited pharmacies undergo on-site inspections, submit to random sample testing, and must demonstrate documented quality systems. As of 2024, fewer than 500 pharmacies hold PCAB accreditation out of an estimated 7,500 compounding pharmacies operating in the United States. Start there.

PCAB accreditation does not guarantee FDA approval of the compounded product, but it significantly narrows the field of pharmacies likely to produce a defensible CoA.

Questions to Ask Before Ordering

Ask the pharmacy these specific questions before placing any order:

1. Do you use a third-party ISO 17025-accredited laboratory for HPLC purity, identity, sterility, and endotoxin testing?
2. Can you provide the full CoA, including the chromatogram and raw mass spectrometry data, before I receive the vial?
3. What is the FDA registration number of your API supplier?
4. What is the cleanroom classification of your sterile compounding suite (ISO 5 laminar flow hood within ISO 7 buffer room is the USP <797> minimum)?
5. What beyond-use dating policy do you apply, and is it supported by stability testing?

A pharmacy that cannot answer all five questions in writing is not a pharmacy you should be sourcing from.

Red Flags That Disqualify a Supplier

• No CoA available, or CoA provided only after payment.
• CoA signed by the pharmacy's own pharmacist with no independent lab reference.
• Purity stated as "greater than 95%" without a specific value.
• Sterility result listed as "tested" rather than "pass" or "conforms."
• No endotoxin result at all.
• Price significantly below market (typically below $80 per 2 mg vial from a US pharmacy signals corner-cutting on testing).
• Shipping without a prescription from a licensed prescriber.

The last point matters legally. Under both 503A and state pharmacy law, a patient-specific prescription is required for a compounding pharmacy to dispense CJC-1295 to an individual. Pharmacies selling without a prescription are operating outside federal and state law. [4]

Is CJC-1295 Legal? The Honest Answer

CJC-1295 is not FDA-approved for any indication. It is not a controlled substance under the DEA's schedule, but it is a prescription drug under federal law because it is administered by injection and requires prescriber oversight. [4]

Compounding it is legal when:

• A licensed prescriber writes a patient-specific prescription.
• A state-licensed 503A compounding pharmacy fills that prescription.
• The pharmacy uses USP-grade or equivalent API from an FDA-registered supplier.
• The preparation meets USP <797> sterile compounding standards.

Selling CJC-1295 as a "research chemical" for human use, without a prescription, or through an unlicensed website does not meet those conditions. The FDA has sent warning letters to multiple online peptide sellers for marketing injectable compounds without prescriptions, citing misbranding and adulteration violations. [10]

The World Anti-Doping Agency (WADA) lists CJC-1295 as a prohibited substance in competition under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Athletes subject to WADA testing should be aware that a compounded preparation carries the same prohibition as any other form. [11]

CJC-1295 Pharmacology: Why These Quality Standards Matter Clinically

CJC-1295 stimulates pulsatile growth hormone (GH) secretion from the anterior pituitary by binding to the GHRH receptor. A 2006 clinical study by Jetté and colleagues (N=66) showed that CJC-1295 with DAC produced dose-dependent increases in mean GH concentrations, with GH levels elevated for up to 6 days after a single injection and IGF-1 levels rising by 28% to 43% above baseline at doses of 30 to 60 mcg/kg. [3]

That prolonged GH elevation is the therapeutic rationale behind using CJC-1295, but it also means a dosing error from an incorrectly labeled concentration is not corrected within hours. An injection of a vial labeled 2 mg/mL that is actually 4 mg/mL delivers twice the intended GH stimulus for up to 6 days. Potency verification on the CoA is not a technicality. It is the difference between a therapeutic and a supraphysiologic GH exposure.

GH excess, even transient, carries risks including fluid retention, carpal tunnel syndrome, and insulin resistance. A 2019 review in the Journal of Clinical Endocrinology and Metabolism noted that supraphysiologic GH increases fasting insulin and reduces insulin sensitivity in a dose-dependent manner. [12] Accurate concentration on the CoA directly protects against that outcome.

Environmental Monitoring Data: What the Pharmacy Should Be Able to Share

USP <797> (2023) mandates that compounding facilities perform routine environmental monitoring (EM), including viable air sampling, surface sampling, and personnel sampling. Results are recorded and trended. A pharmacy with a mature quality system can share a summary of its EM program, including action and alert levels and the frequency of excursions, on request.

You will not typically see EM data on a product-specific CoA, but asking for a one-page EM summary is a reasonable due-diligence step. Pharmacies with consistent ISO 5 viable air counts below the USP action level of 1 CFU per cubic meter (for ISO 5 areas) demonstrate process control. Pharmacies that cannot produce EM records are not operating a compliant clean room. [6]

Verifying the Testing Laboratory

The independent laboratory named on the CoA should be verifiable through the ISO/IEC 17025 accreditation registry, maintained by the American Association for Laboratory Accreditation (A2LA) or similar accreditation bodies. Before accepting a CoA, confirm:

1. The lab's name on the CoA matches the name in the A2LA registry.
2. The accreditation scope includes pharmaceutical analysis (peptide purity, sterility, endotoxin).
3. The accreditation was current on the date the testing was performed.

A lab that appears in no registry, or whose scope does not cover pharmaceutical analysis, cannot be treated as a qualified independent source. The FDA's guidance on analytical procedures for drug substances and products specifies validation requirements for laboratory methods. [13]